The Illinois Department of Healthcare and Family Services (HFS) has taken a significant step toward improving treatment access and affordability for Sickle Cell Disease (SCD) patients by issuing its first comprehensive report on gene and cell therapy treatments. This report, generated in
January 13, 2025The landscape of cancer therapy is undergoing a transformative shift with the advent of in vivo CAR-T cell therapies. These innovative treatments promise to simplify, accelerate, and reduce the costs of cancer care, marking a significant departure from traditional ex vivo methods. This article
January 13, 2025The Blood and Cell Advocacy Register (BCAR) is a newly launched consortium that aims to revolutionize the development and commercialization of advanced therapy medicinal products (ATMPs). Formed in December 2024, BCAR brings together experts and organizations from the blood and cell industries to
January 10, 2025The advancements in muscle regeneration technology by Swiss biotech company MUVON Therapeutics are making waves, especially in the realm of treating stress urinary incontinence in women. This breakthrough holds the potential to improve the quality of life for millions while extending healthspan.
January 10, 2025In a groundbreaking partnership aimed at revolutionizing the production processes for stem cell-based therapies, Mytos has joined forces with Aspen Neuroscience to enhance the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs). These cells are integral to Aspen’s ANPD001, an
January 9, 2025Penn Medicine’s Center for Cellular Immunotherapies (CCI) is at the forefront of revolutionizing cancer treatment through CAR (chimeric antigen receptor) T cell therapy. This innovative approach harnesses the power of the patient’s own immune system to target and destroy cancer cells, offering new h
January 8, 2025